Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667820 · ClinicalTrials.gov registry record · Phase 2
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT03667820: Active Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by University of Texas Southwestern Medical Center.
NCT03667820 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 41 participants, below the 284-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03667820, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).
Primary Outcome
Progression-Free Survival (PFS) as determined by RECIST 1.1 or death (in the absence of progression).
Conditions Studied
Interventions
- DRUG Osimertinib
- RADIATION SABR
Study Locations (2)
California
- City of Hope Medical Center - Duarte
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What the registry record for NCT03667820 still lists
NCT03667820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 284-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT03667820 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT03667820 about?
NCT03667820 is a clinical study titled "Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC". This study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).
What is the current status of trial NCT03667820?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2018-09-26. Estimated completion is 2027-09-30.
What conditions does trial NCT03667820 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT03667820?
The interventions under investigation include: Osimertinib (DRUG), SABR (RADIATION).
Who is sponsoring clinical trial NCT03667820?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03667820 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03667820's enrollment target sits among peer trials
41 46th of 59 higher than 14 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
RECRUITING · Phase 2
-
Pembrolizumab for Advanced NSCLC and PS 2-3
RECRUITING · Phase 2
-
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ACTIVE NOT RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI